COMMUNIQUÉS West-GlobeNewswire

Commure Ambient AI Achieves Class I Certification and MHRA Registration
03/09/2026
AI-Powered Clinical Documentation Self-Certified for Immediate UK and EU Deployment MOUNTAIN VIEW, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Commure today announced that Commure Ambient AI , its widely deployed AI [...]
ONWARD Medical Announces First Implant in New Clinical Feasibility Study Evaluating ARC-IM System to Restore Mobility After Spinal Cord Injury
03/09/2026
The EIGER study will assess the safety and preliminary effectiveness of the investigational ARC-IM ® System to restore mobility after both subacute and chronic spinal cord injury ARC-IM is an implanted neuromodulation [...]
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China
03/09/2026
The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer’s Disease, a Progressive Neurodegenerative Disease TOKYO and CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eisai [...]
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
03/09/2026
— Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (“ATTC”), which is expected to enter clinical trials in H2 2026 — — HUTCHMED webcasts today at 4:30 p.m. HKT in Chinese ( [...]
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026
02/09/2026
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE [...]
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 août 2026
02/09/2026
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 août 2026 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE [...]
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
02/09/2026
Results support the clinical rationale for RASolve 301, an ongoing Phase 3 trial in RAS mutant metastatic non-small cell lung cancer REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. ( [...]
Surrozen to Present at Upcoming Healthcare Investor Conferences
02/09/2026
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling [...]
Shattuck Labs Announces Participation in Upcoming September Investor Conferences
02/09/2026
AUSTIN, Texas and DURHAM, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in- [...]
Kyverna Therapeutics to Present at Upcoming Investor Conferences
02/09/2026
EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune [...]
Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference
02/09/2026
GAITHERSBURG, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive [...]
Amwell® to participate in upcoming investor conferences
02/09/2026
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of technology enabled care, today announced that members of the Amwell management team will participate in the following upcoming [...]
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
02/09/2026
SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib [...]
Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
02/09/2026
Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing technology designed to deliver ultra-long-acting cholesterol lowering [...]
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/09/2026
NEW HOPE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through [...]
Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse Patients
02/09/2026
REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse Patients Reports an Apnea-Hypopnea Index (AHI) responder [...]
Nyxoah Annonce que l'Étude Pivot Américaine ACCCESS Atteint ses Critères Principaux de Sécurité et d'Efficacité chez les Patients Présentant un Collapsus Concentrique Complet
02/09/2026
INFORMATIONS RÉGLEMENTÉES INFORMATIONS PRIVILÉGIÉES Nyxoah Annonce que l'Étude Pivot Américaine ACCCESS Atteint ses Critères Principaux de Sécurité et d'Efficacité chez les Patients Présentant un Collapsus Concentrique [...]
Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH
02/09/2026
Last patient completed final 72-week visit in NATiV3, with 1,009 patients enrolled in the main cohort and 410 patients in the exploratory cohort Topline results of NATiV3 expected in Q4 2026 September investor [...]
Inventiva annonce la dernière visite du dernier patient de l’étude clinique de Phase 3 NATiV3 évaluant le lanifibranor dans la MASH
02/09/2026
Le dernier patient de l’étude NATiV3 a désormais réalisé sa dernière visite à 72 semaines, portant à 1 009 le nombre de patients inclus dans la cohorte principale et à 410 celui de la cohorte exploratoire. Les résultats [...]

Pages